 |
|
Researchers identify gene that regulates tumors in neuroblastoma
June 02, 2009Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
According to Paul B. Fisher, M.Ph., Ph.D., who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center, and Seok-Geun Lee, Ph.D., assistant professor in the VCU Department of Human and Molecular Genetics, co-lead investigators of the study, the team has shown that astrocyte elevated gene-1, AEG-1, a cancer promoting gene, is frequently activated in neuroblastoma.
In the study published online in the May issue of the journal Oncogene, Fisher, Lee and their team found that the elevated expression of AEG-1 makes cancer cells highly aggressive and resistant to factors that may influence cell suicide, and that loss of AEG-1 reduces the tumor-causing properties of highly aggressive neuroblastoma cells. Additionally, the expression of AEG-1 was significantly elevated in six of 10 neuroblastoma patient-derived samples compared to normal peripheral nerve tissues.
Furthermore, they have shown the potential correlation between AEG-1 and MYCN in neuroblastoma. MYCN is a known genetic determinant of neuroblastoma and elevated levels have been observed in one third of neuroblastoma patients. MYCN is linked to aggressive tumor formation and poor clinical outcome.
"We believe that activation of AEG-1 in addition to MYCN is critical to the development and progression of neuroblastoma. This works shows that AEG-1 plays a crucial role in the development and progression of neuroblastoma through activating important signaling pathway and induction of MYCN," said Fisher, who also is professor and chair of the Department of Human and Molecular Genetics, and director of the VCU Institute of Molecular Medicine in the VCU School of Medicine.
"In addition, we have shown that AEG-1 could be a potential prognostic marker for neuroblastoma and a potential target for novel therapeutic strategies for neuroblastoma patients," he said.
The team has already begun analyzing the expression of AEG-1 and its relationship with MYCN status in neuroblastoma patient samples. Through collaboration with John Maris, M.D., chair of neuroblastoma research at the University of Pennsylvania School of Medicine, the team will acquire data from approximately 2,000 neuroblastoma patient tissues. They will also test if inactivation of AEG-1 using small interfering RNA could be a therapeutic intervention for neuroblastoma through second collaborative effort with Bill Weiss, M.D., associate professor of Neurology at the University of California, San Francisco.
This work was supported by grants from the National Institutes of Health, the Samuel Waxman Cancer Research Foundation, the Dana Foundation, and the Goldhirsh Foundation.
Fisher worked with a team that included VCU School of Medicine researchers Zaozhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; H-Y Jeon, J.E. Richards, and N. Vozhilla, D.V.M., with the VCU Department of Human and Molecular Genetics; and T Van Maerken, M.D., with the Center for Medical Genetics at the Ghent University Hospital in Ghent, Belgium.
Virginia Commonwealth University
Furthermore, they have shown the potential correlation between AEG-1 and MYCN in neuroblastoma. MYCN is a known genetic determinant of neuroblastoma and elevated levels have been observed in one third of neuroblastoma patients. MYCN is linked to aggressive tumor formation and poor clinical outcome.
"We believe that activation of AEG-1 in addition to MYCN is critical to the development and progression of neuroblastoma. This works shows that AEG-1 plays a crucial role in the development and progression of neuroblastoma through activating important signaling pathway and induction of MYCN," said Fisher, who also is professor and chair of the Department of Human and Molecular Genetics, and director of the VCU Institute of Molecular Medicine in the VCU School of Medicine.
"In addition, we have shown that AEG-1 could be a potential prognostic marker for neuroblastoma and a potential target for novel therapeutic strategies for neuroblastoma patients," he said.
The team has already begun analyzing the expression of AEG-1 and its relationship with MYCN status in neuroblastoma patient samples. Through collaboration with John Maris, M.D., chair of neuroblastoma research at the University of Pennsylvania School of Medicine, the team will acquire data from approximately 2,000 neuroblastoma patient tissues. They will also test if inactivation of AEG-1 using small interfering RNA could be a therapeutic intervention for neuroblastoma through second collaborative effort with Bill Weiss, M.D., associate professor of Neurology at the University of California, San Francisco.
This work was supported by grants from the National Institutes of Health, the Samuel Waxman Cancer Research Foundation, the Dana Foundation, and the Goldhirsh Foundation.
Fisher worked with a team that included VCU School of Medicine researchers Zaozhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, M.B.B.S., Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; H-Y Jeon, J.E. Richards, and N. Vozhilla, D.V.M., with the VCU Department of Human and Molecular Genetics; and T Van Maerken, M.D., with the Center for Medical Genetics at the Ghent University Hospital in Ghent, Belgium.
Virginia Commonwealth University
Neuroblastoma Current Events and Neuroblastoma News RSSWeizmann Institute Scientists Discover A New Protein Partnership That Leads to Pediatric Tumor Regression
Why are some pediatric cancers able to spontaneously regress? Prof. Michael Fainzilber and his team of the Weizmann Institute's Biological Chemistry Department seem to have unexpectedly found part of the answer.
PET Can Help Guide Treatment Decisions for a Common Pediatric Cancer
A new study published in the August issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) is an important tool for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Protein That Promotes Cancer Cell Growth Identified
Scientists at Burnham Institute for Medical Research (Burnham) have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues.
U of M Researchers Find Childhood Cancer Risk Rises with Mother's Age
Research from the Masonic Cancer Center, University of Minnesota indicates that a baby born to an older mother may have a slightly increased risk for many of the cancers that occur during childhood.
Variations in 5 genes raise risk for most common brain tumors
Common genetic variations spread across five genes raise a person's risk of developing the most frequent type of brain tumor, an international research team reports online in Nature Genetics.
Genetic finding could lead to targeted therapy for neuroblastoma
Researchers have identified a genetic glitch that could lead to development of neuroblastoma, a deadly form of cancer that typically strikes children under 2.
New therapy enlists immune system to boost cure rate in a childhood cancer
A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.
Immunotherapy effective against neuroblastoma in children
A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma.
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders tumor growth in neuroblastoma, a childhood cancer.
Drug inhibits neuroblastoma blood supply in pre-clinical tests
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a way to prevent blood vessels from aiding the growth of neuroblastoma, a childhood cancer.
More Neuroblastoma Current Events and Neuroblastoma News Articles
 |
Neuroblastoma by Nai-Kong V. Cheung (Editor), Susan L. Cohn (Editor) Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology, and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma... |
 |
Fight Against Neuroblastoma Sweatshirt X-Large White by Shop Zeus |
 |
Cure Neuroblastoma Keychain by Design a Product LLC Text on keychain: Cure Neuroblastoma * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
![Neuroblastoma Injected By Viral Oestogena [Explicit]](http://ecx.images-amazon.com/images/I/41anx1tCcwL._SL160_.jpg) |
Neuroblastoma Injected By Viral Oestogena [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
 |
Neuroblastoma Awareness Ribbon Mouse Pad by MyHeritageWear.com The Neuroblastoma Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Neuroblastoma Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Neuroblastoma Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Neuroblastoma by Velvet Acid Christ |
 |
Neuroblastoma Research Trends by Lucas H. Andre (Editor), Nathan E. Roux (Editor) Neuroblastoma is a cancer that develops from nerve cells found in several areas of the body. Neuroblastoma most commonly affects children age 5 or younger, though it may rarely occur in older children and adults. Neuroblastoma is the most common cancer in babies. Neuroblastoma develops in tissue that makes up the sympathetic nervous system - the system of nerves that automatically regulates your heart rate, blood pressure and digestion. Neuroblastoma most commonly arises in and around the adrenal glands, which sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the chest, neck and pelvis. This book presents important new research in this field of research. |
 |
Cure Neuroblastoma Long Sleeve T-shirt Large White by Shop Zeus |
 |
Neuroblastoma: Tumor Biology and Therapy by Carl E. Pochedly (Author) The purpose of this book is to provide a comprehensive review of current knowledge and to give a thoughtful assessment of the many complex issues involved in the diagnosis and treatment of this common malignant solid tumor found in children. This up-to-date publication also reviews new concepts in histogenesis and histopathology of neuroblastoma. Divided into three main sections, this work focuses on tumor biology, clinical management, and prognosis and future perspectives. This fascinating work includes in-depth discussions on neuroblastoma in infancy and the manifestations of this tumor as it affects various organs and various parts of the body. It also provides guidelines for treatment with surgery, radiotherapy and chemotherapy. This ideal resource is loaded with information for all... |
 |
The Epidemiology of Neuroblastoma by Stefano Parodi (Author), Riccardo Haupt (Author) Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common tumor in the first year of life and the most common solid extra-cranial cancer in childhood. Neuroblastoma represents an enigmatic disease, in that some cases, especially in infants, tend to spontaneously regress, even in advanced states, while many patients are refractary to any therapeutical approach and show an inexorable clinical course. As most of the other solid cancers in children, the distribution of Neuroblastoma risk worldwide is only partly known. In Western countries, its incidence varies between 7 and 16 cases per million children and it tends to decrease increasing the age.Besides, survival of patients affected by such disease, in relation with clinical and biological characteristics, have... |
| © 2009 BrightSurf.com |